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Abstract. The study of antithrombotic efficacy, safety and tolerability of aspirin generic in patients with 
coronary heart disease. T.A. Khomaziuk, L.I. Novozhenina, . . Levykh, S.I. Kryzhanovska, V.I. Hrytsenko. 
The aim of the study was to investigate the antithrombotic efficiency, safety and tolerance of Lospirintm in patients with 
coronary artery disease. The study involved 50 patients (32 men and 18 women) aged 40-65 years with disease duration from 
3 to 27 years, receiving daily one tablet of Lospirintm (75 mg) for 28 days as an antiplatelet agent in addition to basic therapy. 
General clinical data, hemodynamic parameters, laboratory results of blood tests, urine and agregant state of blood plasma 
were assessed. During the period of drug application side effects/reactions were not registered. Tolerance of Lospirintm was 
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